NDAINHALATIONPOWDERPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
TYVASO DPI (treprostinil) by United Therapeutics is beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation. Approved for pulmonary arterial hypertension, pulmonary hypertension. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYVASO DPI is an inhaled powder formulation of treprostinil, a prostacyclin vasodilator approved by the FDA in May 2022. It is indicated for pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and improve exercise capacity. The drug works through vasodilation of pulmonary and systemic arterial beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation. As a novel inhalation delivery format for treprostinil, it offers patients an alternative to parenteral or oral formulations in the PAH treatment landscape.
$0.4BPart D
15.8 years to LOEMechanism of Action
beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation.
Pharmacologic Class:
Prostacycline Vasodilator
Indications (2)
Worked on TYVASO DPI at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.